FRISCH BACILLUS (RHINOSCLEROMA) - 20 Mark RGUHS Answer

INTRODUCTION / DEFINITION

Sources: Cummings Otolaryngology, p. 1008 | Scott-Brown's Otorhinolaryngology | Fitzpatrick's Dermatology, p. 2838 | Andrews' Diseases of the Skin

HISTORICAL BACKGROUND

ETIOLOGY AND MICROBIOLOGY

┌─────────────────────────────────────────────────────────────────┐
│              FRISCH BACILLUS (Klebsiella rhinoscleromatis)       │
├─────────────────────────────────────────────────────────────────┤
│  Classification : Klebsiella pneumoniae subspecies              │
│                  rhinoscleromatis                               │
│  Family        : Enterobacteriaceae                             │
│  Shape         : Rod-shaped (Diplobacillus), 2-3 μm            │
│  Gram stain    : Gram-NEGATIVE                                  │
│  Motility      : NON-MOTILE                                     │
│  Capsule       : ENCAPSULATED (gelatinous capsule)             │
│  Metabolism    : Facultative intracellular                      │
│  Lactose       : Lactose-fermenting                             │
│  Culture       : MacConkey agar                                 │
│  Special note  : Difficult to isolate; cultures +ve in only     │
│                  50-60% of cases                                │
└─────────────────────────────────────────────────────────────────┘

Cummings Otolaryngology, p. 1008 | Andrews' Diseases of the Skin, p. 929

EPIDEMIOLOGY

• Globally endemic in: Central and South America, Central Africa, Middle East, Eastern Europe, Southeast Asia (India, Indonesia, China)
• India: More common in northern states (North India > South India)
• Age: Most common in 2nd and 3rd decades (10-30 years); any age possible
• Sex: Female > Male (slight to marked female preponderance; KJ Lee: 13:1 F:M ratio)
• Socioeconomic factors: Poor nutrition, poor hygiene, crowded living conditions, low socioeconomic status
• Incidence in USA: Rare (predominantly an imported tropical disease)

K.J. Lee's Essential Otolaryngology, p. 8101-8103 | Cummings, p. 1008

PATHOGENESIS

FLOW CHART: PATHOGENESIS OF RHINOSCLEROMA
══════════════════════════════════════════

  Inhalation of contaminated respiratory droplets
  or contaminated material
          │
          ▼
  Colonization at EPITHELIAL TRANSITION ZONES
  (nasal vestibule, larynx, etc.)
          │
          ▼
  Iron deficiency + DEFECTIVE CELLULAR IMMUNITY
          │
          ▼
  Klebsiella rhinoscleromatis evades phagocytic killing
  (remains viable inside macrophages)
          │
          ▼
  Macrophages engulf bacilli → MIKULICZ CELLS formed
  (foamy vacuolated histiocytes containing live bacilli)
          │
          ▼
  Granulomatous inflammation in submucosa
  (plasma cells, lymphocytes, eosinophils, Russell bodies)
          │
          ▼
  Progressive granuloma → Fibrosis → SCLEROSIS

Fitzpatrick's Dermatology, p. 2838 | Cummings, p. 1008

SITES OF INVOLVEMENT

ANATOMICAL SPREAD (in order of frequency):

  NOSE (95-100%)  →  NASOPHARYNX (18-43%)
      │
      ▼
  LARYNX (15-80%)  →  TRACHEA (12%)
      │
      ▼
  BRONCHI (2-7%)  →  PARANASAL SINUSES
      │
      ▼
  OROPHARYNX (absent uvula)  →  ORBIT (rare)

Most commonly affected sites in nasal cavity:
  → Middle turbinate
  → Inferior turbinate
  → Nasal vestibule (onset)

• Glottis and subglottis are the main areas involved in the larynx.

Scott-Brown's, p. 4284 | Cummings, p. 1008 | K.J. Lee's, p. 8105

CLINICAL STAGES

FLOW CHART: STAGES OF RHINOSCLEROMA
═══════════════════════════════════════════════════════════

  STAGE 1: CATARRHAL / RHINITIC STAGE (Atrophic stage)
  ─────────────────────────────────────────────────────
  Duration   : Months (non-specific)
  Features   : • Persistent purulent rhinorrhoea
               • Nasal crusting (honey-coloured)
               • Nasal obstruction
               • Foul-smelling discharge
               • Symptoms of common cold
  Histology  : Mild, non-specific inflammation only
          │
          ▼
  STAGE 2: GRANULOMATOUS / PROLIFERATIVE / FLORID STAGE
  ──────────────────────────────────────────────────────
  Duration   : Months to years
  Features   : • Painless hard granulomatous nodules
                 in nose and URT
               • Nasal deformity ("Hebra nose" /
                 Tapir nose - broadened, irregular nose)
               • Septal destruction
               • Thickened soft palate (absent uvula)
               • Anosmia, hyposmia
               • Dysphagia (oropharyngeal involvement)
               • Dysphonia (laryngeal involvement)
               • Stridor (tracheal/laryngeal)
               • Epistaxis
  Histology  : PATHOGNOMONIC FINDINGS:
               • Mikulicz cells + Russell bodies
               • Plasma cells, lymphocytes
               • Pseudoepitheliomatous hyperplasia
          │
          ▼
  STAGE 3: SCLEROTIC / CICATRICIAL / FIBROTIC STAGE
  ──────────────────────────────────────────────────
  Duration   : End stage
  Features   : • Extensive dense fibrosis and scarring
               • Narrowing of nasal passages (anosmia)
               • Airway stenosis (subglottic stenosis)
               • Dysphonia, stridor
               • Nasal deformity (permanent)
               • Complete obstruction of nares
               • Seropurulent exudation
  Histology  : Dense fibrous tissue, scant inflammation

K.J. Lee, p. 8111-8117 | Cummings, p. 1008 | Andrews', p. 920-927 | Scott-Brown's

CLINICAL PHOTOGRAPH

PATHOLOGY / HISTOPATHOLOGY

HISTOPATHOLOGICAL DIAGRAM

    SUBMUCOSA OF RHINOSCLEROMA
    ═══════════════════════════════════════════════
    
    ┌──────────────────────────────────────────────┐
    │  SURFACE EPITHELIUM                          │
    │  (pseudoepitheliomatous hyperplasia)         │
    ├──────────────────────────────────────────────┤
    │                                              │
    │  GRANULOMATOUS INFILTRATE:                   │
    │                                              │
    │  ┌─────────────────────┐                     │
    │  │  MIKULICZ CELL      │ ← PATHOGNOMONIC     │
    │  │  (Large vacuolated  │                     │
    │  │   macrophage with   │                     │
    │  │   clear cytoplasm   │                     │
    │  │   containing Frisch │                     │
    │  │   bacilli)          │                     │
    │  │   CD68 positive     │                     │
    │  └─────────────────────┘                     │
    │                                              │
    │  ┌─────────────────────┐                     │
    │  │  RUSSELL BODIES     │ ← PATHOGNOMONIC     │
    │  │  (Bloated plasma    │                     │
    │  │   cells with        │                     │
    │  │   birefringent      │                     │
    │  │   eosinophilic      │                     │
    │  │   inclusions /      │                     │
    │  │   Ig deposits)      │                     │
    │  └─────────────────────┘                     │
    │                                              │
    │  + Plasma cells    + Lymphocytes             │
    │  + Eosinophils     + Spindle cells           │
    │  + Fibrosis (in cicatricial stage)           │
    └──────────────────────────────────────────────┘

Cummings, p. 1008 | Fitzpatrick's, p. 2043 | Andrews', p. 933

INVESTIGATIONS

DIAGNOSTIC ALGORITHM FOR RHINOSCLEROMA
══════════════════════════════════════════════════════

Clinical suspicion
(nasal obstruction + granulomatous lesion + endemic area)
          │
          ▼
  ┌──────────────────────────────────────────┐
  │         STEP 1: NASAL ENDOSCOPY         │
  │  • Granulomatous nodules                │
  │  • Extensive crusting                   │
  │  • Middle & inferior turbinates most    │
  │    commonly affected                    │
  └──────────────────────────────────────────┘
          │
          ▼
  ┌──────────────────────────────────────────┐
  │          STEP 2: IMAGING (CT Scan)       │
  │  • Non-enhancing homogeneous soft-       │
  │    tissue mass                          │
  │  • Nodular deformity, distinct edges     │
  │  • Larynx/trachea: concentric irregular  │
  │    airway narrowing                     │
  │  • No bone destruction                  │
  └──────────────────────────────────────────┘
          │
          ▼
  ┌──────────────────────────────────────────┐
  │       STEP 3: TISSUE BIOPSY             │
  │  (Gold standard for diagnosis)          │
  │                                         │
  │  HISTOPATHOLOGY:                        │
  │  • Mikulicz cells (pathognomonic)       │
  │  • Russell bodies (pathognomonic)       │
  │  • Plasma cells, lymphocytes            │
  │  • Pseudoepitheliomatous hyperplasia    │
  │                                         │
  │  CULTURE (MacConkey agar):              │
  │  • Positive in only 50-60% of cases     │
  │  • Klebsiella rhinoscleromatis grows    │
  └──────────────────────────────────────────┘
          │
          ▼
  ┌──────────────────────────────────────────┐
  │       STEP 4: SEROLOGICAL TESTS         │
  │  • Complement fixation test             │
  │    (heat-killed antigen - confirmatory) │
  │  • Specific antibody titers             │
  └──────────────────────────────────────────┘
          │
          ▼
       CONFIRMED DIAGNOSIS

Cummings, p. 1008 | Fitzpatrick's, p. 2043 | Andrews', p. 934

DIFFERENTIAL DIAGNOSIS

CONDITIONS TO DIFFERENTIATE FROM RHINOSCLEROMA:

  GRANULOMATOUS/INFECTIOUS:
  ├── Tuberculosis (Lupus vulgaris)
  ├── Leprosy (Hanseniasis)
  ├── Syphilitic gumma (Tertiary syphilis)
  ├── Sarcoidosis
  ├── Rhinosporidiosis
  ├── Mucocutaneous Leishmaniasis
  ├── Dimorphic fungal infections
  │   (Histoplasmosis, Paracoccidioidomycosis)
  ├── Yaws (Frambesia)
  └── Wegener's (Granulomatosis with polyangiitis)

  NEOPLASTIC:
  ├── Squamous cell carcinoma
  ├── Basal cell carcinoma
  ├── Lymphoma
  └── Inverting papilloma

Fitzpatrick's, p. 2043 | Andrews', p. 935 | Scott-Brown's

TREATMENT

MANAGEMENT FLOW CHART
══════════════════════════════════════════════════════

DIAGNOSIS CONFIRMED
          │
          ├────────────────┬─────────────────┐
          ▼                ▼                 ▼
   MEDICAL Rx        SURGICAL Rx       FOLLOW-UP
          │                │
          ▼                ▼
  ANTIBIOTICS:        INDICATIONS:
  ─────────────       ─────────────
  First-line:         • Nasal debridement
  CIPROFLOXACIN         (alleviate crusting
  (Drug of choice       and obstruction)
  per Cummings)       • CO₂ laser excision
                        (airway lesions)
  Other options:      • Tracheostomy
  • Tetracycline        (severe subglottic
    2g/day              stenosis/stridor)
  • Rifampicin        • Reconstructive
    450mg/day           surgery
  • Trimethoprim-       (AFTER disease
    sulfamethoxazole    control, for nasal
  • Doxycycline         deformity)
  • Streptomycin      • Endoscopic
    1g IM               excision
  • Cephalosporins    • Septoplasty
                        ONLY after active
  DURATION:             disease is burnt out
  ──────────          • FESS for sinus
  MINIMUM 3-6           drainage
  months
  Continue until
  repeat cultures
  AND histology
  are NEGATIVE

  Adjunct:
  • Corticosteroids
    (acute/proliferative
    phase)

1. Ciprofloxacin is the current drug of choice (Cummings, 2024)
2. Traditional regimen: Streptomycin 1g IM + Tetracycline 2g/day for 4-6 weeks
3. Duration must be minimum 3-6 months to prevent relapse
4. Medical therapy MUST precede definitive surgical correction
5. High incidence of relapse despite prolonged therapy
6. Corticosteroids useful in the acute/proliferative phase (Andrews')

Cummings, p. 1008 | K.J. Lee, p. 8127 | Andrews', p. 940 | Scott-Brown's, p. 4288

COMPLICATIONS

RECENT ADVANCES (RGUHS 2024-2026)

1. Molecular Diagnostics

• PCR-based identification of K. rhinoscleromatis from tissue specimens - improves detection sensitivity compared to culture (50-60% sensitivity)
• Molecular typing helps characterize strains and track endemic spread

2. Imaging Advances

• High-resolution CT with 3D reconstruction gives better delineation of airway stenosis extent before surgical planning
• MRI preferred for orbital and intracranial extension assessment

3. Antibiotic Advances

• Ciprofloxacin now firmly established as drug of choice (Cummings, latest edition)
• Rifampicin + Doxycycline combination emerging as effective regimen (2024 case series, Bangalore Command Hospital)
• Prolonged fluoroquinolone therapy (6+ months) reduces relapse rate

4. Endoscopic Surgery

• Functional Endoscopic Sinus Surgery (FESS) using surgical planes to release fibrosis and restore sinus drainage (Belaldavar et al., 2025 - Indian Journal of Otolaryngology - 2-decade experience, 14 patients)
• Endoscopic management avoids disfiguring external approaches

5. 2025 Indian Experience

• Patients frequently misdiagnosed, undergoing unnecessary septoplasty causing septal perforations
• Medical therapy must always precede surgical correction
• Surgical planes help release fibrosis
• Close follow-up essential to monitor recurrence

6. 2026 Case Report (Pune, India)

• Repeat biopsy + immunohistochemistry needed when initial biopsy is inconclusive
• Combination of systemic corticosteroids + prolonged antimicrobial therapy gives significant regression
• Importance of high index of suspicion in endemic areas

7. Granulomatous Disorders Review 2025

• Rhinoscleroma remains an important granulomatous disorder in low-middle income countries
• Overall burden declining with improved socioeconomic conditions
• Timely diagnosis relies on clinical suspicion + blood tests + imaging + histopathology

MEMORY AIDS (RGUHS High-Yield)

Mnemonic: "FRISCH" for key features

F - Frisch bacillus (Klebsiella rhinoscleromatis)
R - Russell bodies (pathognomonic histology)
I - Intracellular (facultative intracellular bacillus)
S - Stages: 3 (Catarrhal → Granulomatous → Sclerotic)
C - Ciprofloxacin (drug of choice)
H - Hebra nose (characteristic deformity) + Histology: Mikulicz cells

Mnemonic: "WARM" for histological stains:
W - Warthin-Starry (gold standard)
A - (PAS) Acid-Schiff
R - Regular Gram stain
M - Mikulicz cells on CD68

SUMMARY TABLE (Quick Revision)

REFERENCES

1. Cummings Otolaryngology Head and Neck Surgery (7th Ed.) - Rhinoscleroma, p. 1008
2. Scott-Brown's Otorhinolaryngology, Head and Neck Surgery - Scleroma, blocks 8 and 10
3. K.J. Lee's Essential Otolaryngology (11th Ed.) - Rhinoscleroma, p. 8097-8127
4. Fitzpatrick's Dermatology (9th Ed.) - Rhinoscleroma, p. 2838
5. Andrews' Diseases of the Skin - Rhinoscleroma, p. 920-940
6. Belaldavar BP et al. "The Panoramic Overview of Rhinoscleroma - A Two-Decade Experience." Indian J Otolaryngol Head Neck Surg, 2025. [PMID: 40321376]
7. Pandharmise R et al. "Rhinoscleroma Masquerading as a Nasal Mass." Cureus, 2026. [PMID: 42292012]
8. Ranganathan B et al. "Granulomatous disorders of the nose in low-middle income countries." Curr Opin Otolaryngol, 2025. [PMID: 40177822]